Drugs / HIV-1 MN rgp160
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00000822 | ? → May 1999 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HIV-1 MN rgp160 | “To evaluate the safety and immunogenicity of HIV-1 MN rgp160 (Immuno-AG) in HIV-infected patients.” NCT00000822 ↗ |
| Known as | Immuno-AG | “To evaluate the safety and immunogenicity of HIV-1 MN rgp160 (Immuno-AG) in HIV-infected patients.” NCT00000822 ↗ |
| Modality | Vaccine | “HIV-1 MN rgp160 Immuno AG Vaccine Therapy” NCT00000822 ↗ |